Comparative Study

. 2022 Feb 14;40(2):114-116.

doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

Annika Fendler¹, Scott T C Shepherd², Lewis Au², Katalin A Wilkinson³, Mary Wu⁴, Andreas M Schmitt⁵, Zayd Tippu², Sheima Farag⁵, Aljosja Rogiers⁵, Ruth Harvey⁶, Eleanor Carlyle⁵, Kim Edmonds⁵, Lyra Del Rosario⁵, Karla Lingard⁵, Mary Mangwende⁵, Lucy Holt⁵, Hamid Ahmod⁵, Justine Korteweg⁵, Tara Foley⁵, Taja Barber¹, Andrea Emslie-Henry¹, Niamh Caulfield-Lynch¹, Fiona Byrne¹, Benjamin Shum², Camille L Gerard¹, Daqi Deng¹, Svend Kjaer⁷, Ok-Ryul Song⁴, Christophe Queval⁴, Caitlin Kavanagh⁴, Emma C Wall⁸, Edward J Carr⁹, Sina Namjou¹⁰, Simon Caidan¹⁰, Mike Gavrielides¹¹, James I MacRae¹², Gavin Kelly¹³, Kema Peat⁵, Denise Kelly⁵, Aida Murra⁵, Kayleigh Kelly⁵, Molly O'Flaherty⁵, Robyn L Shea¹⁴, Gail Gardner¹⁵, Darren Murray¹⁵, Nadia Yousaf¹⁶, Shaman Jhanji¹⁷, Nicholas Van As¹⁸, Kate Young⁵, Andrew J S Furness⁵, Lisa Pickering⁵, Rupert Beale¹⁹, Charles Swanton²⁰; Crick COVID19 consortium; Sonia Gandhi²¹, Steve Gamblin²², David L V Bauer²³, George Kassiotis²⁴, Michael Howell⁴, Emma Nicholson²⁵, Susanna Walker²⁶, Robert J Wilkinson²⁷, James Larkin⁵, Samra Turajlic²⁸; CAPTURE consortium

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
³ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa.
⁴ High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
⁵ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
⁶ Worldwide Influenza Centre, The Francis Crick Institute, London, NW1 1AT, UK.
⁷ Structural Biology STP, The Francis Crick Institute, London NW1 1AT, UK.
⁸ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, WC1E 6BT, UK.
⁹ Cell Biology of Infection Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
¹⁰ Safety, Health & Sustainability, The Francis Crick Institute, London, NW1 1AT, UK.
¹¹ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
¹² Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
¹³ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁴ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK; Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK.
¹⁵ Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK.
¹⁶ Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
¹⁷ Anaesthetics, Perioperative Medicine, and Pain Department, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
¹⁸ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK.
¹⁹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, WC1E 6BT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
²⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
²¹ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
²² Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²³ RNA Virus Replication Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²⁴ Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²⁵ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
²⁶ Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
²⁷ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa; Department of Infectious Disease, Imperial College London, London, W12 0NN, UK.
²⁸ Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 34968417
PMCID: PMC8716090
DOI: 10.1016/j.ccell.2021.12.013

Comparative Study

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

Annika Fendler et al. Cancer Cell. 2022.

. 2022 Feb 14;40(2):114-116.

doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.

Authors

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
³ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa.
⁴ High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
⁵ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
⁶ Worldwide Influenza Centre, The Francis Crick Institute, London, NW1 1AT, UK.
⁷ Structural Biology STP, The Francis Crick Institute, London NW1 1AT, UK.
⁸ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, WC1E 6BT, UK.
⁹ Cell Biology of Infection Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
¹⁰ Safety, Health & Sustainability, The Francis Crick Institute, London, NW1 1AT, UK.
¹¹ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
¹² Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
¹³ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁴ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK; Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK.
¹⁵ Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK.
¹⁶ Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
¹⁷ Anaesthetics, Perioperative Medicine, and Pain Department, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
¹⁸ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK.
¹⁹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, WC1E 6BT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
²⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
²¹ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
²² Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²³ RNA Virus Replication Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²⁴ Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
²⁵ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
²⁶ Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
²⁷ Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa; Department of Infectious Disease, Imperial College London, London, W12 0NN, UK.
²⁸ Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 34968417
PMCID: PMC8716090
DOI: 10.1016/j.ccell.2021.12.013

Erratum in

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Shum B, Gerard CL, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Popat S, Yousaf N, Jhanji S, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C; Crick COVID19 consortium; Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S; CAPTURE consortium. Fendler A, et al. Cancer Cell. 2022 Apr 11;40(4):438. doi: 10.1016/j.ccell.2022.03.010. Cancer Cell. 2022. PMID: 35413273 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment in

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Tatham K, Cunningham D, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Larkin J, Turajlic S; CAPTURE consortium. Fendler A, et al. Lancet. 2022 Mar 5;399(10328):905-907. doi: 10.1016/S0140-6736(22)00147-7. Epub 2022 Jan 25. Lancet. 2022. PMID: 35090602 Free PMC article. No abstract available.

References

1. Cele S., Jackson L., Khan K., Khoury D.S., Moyo-Gwete T., Tegally H., Scheepers C., Amoako D., Karim F., Bernstein M., et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021 doi: 10.1101/2021.12.08.21267417. - DOI
1. Ehmsen S., Asmussen A., Jeppesen S.S., Nilsson A.C., Østerlev S., Vestergaard H., Justesen U.S., Johansen I.S., Frederiksen H., Ditzel H.J. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39:1034–1036. - PMC - PubMed
1. Fendler A., Shepherd S.T.C., Au L., Wilkinson K.A., Wu M., Byrne F., Cerrone M., Schmitt A.M., Joharatnam-Hogan N., Shum B., et al. Nature Cancer; 2021. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. - PMC - PubMed
1. Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune Assays Team§. Moderna, Inc. Team§. Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§. United States Government (USG)/CoVPN Biostatistics Team§ Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021;374:eab3435. doi: 10.1126/science.abm3425. - DOI - PubMed
1. Grivas P., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A., et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann. Oncol. 2021;32:787–800. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Supplementary concepts

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

Affiliations

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

Authors

Affiliations

Erratum in

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical